Key Takeaways J&J braces for upcoming approval and launch of nipocalimab, TAR-200 and icotrokinra. New cancer drugs Carvykti, Tecvayli, and Talvey generated $1.3B in H1 2025 sales.The acquisition of Intra-Cellular Therapies adds Caplyta, boosting J&J's neuroscience portfolio.Johnson & Johnson (JNJ) , like any other large drugmaker, boasts a robust R&D pipeline of drugs, with its key focus areas being immunology, oncology and neuroscience.  J&J has rapidly advanced its pipeline this year, attaining significa ...